Category - Developments

Developments

Ocular Therapeutix doses first patients in Phase 2 dry eye disease trial

Ocular Therapeutix (NASDAQ:OCUL) dosed the first patients in its Phase 2 trial evaluating OTX-CSI for the treatment of dry eye disease. The trial will enroll some 105 patients who will receive either one of two...

September 29, 2020

Developments

Forte Biosciences doses first patient in Phase 2 atopic dermatitis trial

Forte Biosciences (NASDAQ:FBRX) dosed the first patient in its Phase 2 trial evaluating FB-401 for the treatment of atopic dermatitis. FB-401 is a topical mixture comprised primarily of three strains of the commensal...

September 29, 2020

Developments

Concert completes enrollment in Phase 2 schizophrenia trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its Phase 2 study evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia. The trial enrolled 325 patients already on a stable course...

September 29, 2020

Developments

Field Trip Psychedelics completes GLP synthesis of FT-104

Closely-held Field Trip Psychedelics successfully completed GLP synthesis of its psychedelic molecule, FT-104. FT-104 is a new chemical substance designed to be a commercially viable alternative to naturally derived...

September 29, 2020

Developments

Imagin Medical to host KOL webcast on Oct. 29

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will host a virtual investor event with key opinion leaders on Oct. 29 at 12:00 pm ET to highlight the potential of the company’s i/Blue...

September 29, 2020

Developments

Soricimed receives $500,000 in Government of Canada funding

Closely-held Soricimed Biopharma received $500,000 in funding from the Government of Canada to support the company’s continued research and development work. The Government of Canada provided the repayable contribution...

September 29, 2020

Developments

Zucara doses first subject in Phase 1 trial of ZT-01

Closely-held Zucara Therapeutics dosed the first subject in its Phase 1 trial of ZT-01, a once-daily somatostatin inhibitor designed to prevent insulin-induced hypoglycemia. The first, single ascending dose portion...

September 29, 2020

Developments

Kane Biotech, Animalcare to form STEM Animal Health

Kane Biotech (TSX-V:KNE) and UK-based Animalcare Group (AIM:ANCR) signed a pact to form STEM Animal Care, a company dedicated to treating biofilm-related ailments in animals. Under the accord, Animalcare will launch...

September 28, 2020

Developments

Leap Therapeutics DKN-01 gets FDA fast track designation for gastric and gastroesophageal junction cancer

The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 fast track designation for gastric and gastroesophageal junction cancer. Specifically, the designation was granted for patients whose tumors express high Dickkopf...

September 24, 2020

Developments

Mereo setrusumab gets FDA rare pediatric disease designation for osteogenesis imperfecta

The FDA granted Mereo BioPharma’s (NASDAQ:MREO) setrusumab rare pediatric disease designation for the treatment of osteogenesis imperfecta (OI). OI, also known as brittle bone disease, is caused by a genetic mutation in...

September 24, 2020

Category - Developments

Ocular Therapeutix doses first patients in Phase 2 dry eye disease trial

Forte Biosciences doses first patient in Phase 2 atopic dermatitis trial

Concert completes enrollment in Phase 2 schizophrenia trial

Field Trip Psychedelics completes GLP synthesis of FT-104

Imagin Medical to host KOL webcast on Oct. 29

Soricimed receives $500,000 in Government of Canada funding

Zucara doses first subject in Phase 1 trial of ZT-01

Kane Biotech, Animalcare to form STEM Animal Health

Leap Therapeutics DKN-01 gets FDA fast track designation for gastric and gastroesophageal junction cancer

Mereo setrusumab gets FDA rare pediatric disease designation for osteogenesis imperfecta

General

More